Cytokinetics (CYTK) PT Raised to $60 at Needham & Company on Higher Price of mavacamten, Focus Remains on omecamtiv PDUFA
Tweet Send to a Friend
Needham & Company analyst Serge Belanger raised the price target on Cytokinetics (NASDAQ: CYTK) to $60.00 (from $52.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
